Grit Bio Closes $60 Million Round for Tumor-Infiltrating Lymphocyte Oncology Drugs
publication date: Sep 8, 2023
Shanghai Grit Biotechnology, a cell therapy company, raised more than $60 million in a Series B financing round to develop its pipeline of drugs based on Tumor-Infiltrating lymphocytes. The company’s lead drug, GT101, has started a pivotal Phase II trial for solid tumor cancers. TIL uses lymphoctyes (T cells and B cells) derived from a tumor biopsy, expands them, and infuses the cells back into the patient. Unlike CAR-T therapies, TIL candidates naturally target the tumor, and they typically attack multiple targets in the tumor. The B Round was led by CICC. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.